Cargando…

Editorial: Novel mechanisms for the treatment of AML before and after transplant

Detalles Bibliográficos
Autor principal:	Kasner, Margaret T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660237/ https://www.ncbi.nlm.nih.gov/pubmed/36387087 http://dx.doi.org/10.3389/fonc.2022.1063307

Ejemplares similares

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience
por: Wilde, Lindsay, et al.
Publicado: (2020)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse
por: Salhotra, Amandeep, et al.
Publicado: (2022)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
por: van de Donk, Niels W. C. J., et al.
Publicado: (2020)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
por: Möröy, Tarik, et al.
Publicado: (2019)

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
por: Mendez, Lourdes M., et al.
Publicado: (2019)

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
por: D’Agostino, Mattia, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

The Graft-Versus-Leukemia Effect in AML
por: Sweeney, Connor, et al.
Publicado: (2019)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

Co-management strategies for acute myeloid leukemia patients in the community setting
por: Benton, Christopher, et al.
Publicado: (2022)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Editorial: Advances in the Molecular Mechanisms in Gastrointestinal Tumorigenesis and Treatment
por: Zhang, Ruowen, et al.
Publicado: (2022)

Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors
por: Suenaga, Yusuke, et al.
Publicado: (2021)

Editorial: 50 years of BMT: long-term outcomes and late complications after transplantation
por: Gavriilaki, Eleni
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Towards a Better Understanding of Cohesin Mutations in AML
por: Cuartero, Sergi, et al.
Publicado: (2019)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer
por: Lam, Alfred King-yin, et al.
Publicado: (2022)

Editorial: Novel Combination Therapies for the Treatment of Solid Cancers
por: Ayoub, Nehad M.
Publicado: (2021)

Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond
por: Keiffer, Gina, et al.
Publicado: (2020)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v2t870go2bsn9b7o1skg9u4k3k